{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:08:30Z","timestamp":1783908510003,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Beijing Natural Science Foundation","award":["No.7244461"],"award-info":[{"award-number":["No.7244461"]}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["No.Z230021"],"award-info":[{"award-number":["No.Z230021"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chronic Disease Management Research Project of National Health Commission Capacity Building and Continuing Education Center","award":["GWJJMB202510041118"],"award-info":[{"award-number":["GWJJMB202510041118"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00210-026-05290-0","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T11:55:14Z","timestamp":1775649314000},"page":"14055-14065","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world prescription patterns of guideline-recommended therapies in heart failure across China"],"prefix":"10.1007","volume":"399","author":[{"given":"Yingming","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanqing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongge","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenning","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"issue":"4","key":"5290_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.cardfail.2024.08.059","volume":"31","author":"S Agrawal","year":"2025","unstructured":"Agrawal S, Alhaddad Z, Nabia S et al (2025) Prescription patterns in management of heart failure and its association with readmissions: a retrospective analysis. J Card Fail 31(4):635\u2013645. https:\/\/doi.org\/10.1016\/j.cardfail.2024.08.059","journal-title":"J Card Fail"},{"issue":"16","key":"5290_CR2","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"issue":"5","key":"5290_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.4093\/dmj.2022.0002","volume":"46","author":"JH Baek","year":"2022","unstructured":"Baek JH, Yang YS, Ko S et al (2022) Real-world prescription patterns and barriers related to the use of sodium-glucose cotransporter 2 inhibitors among Korean patients with type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab J 46(5):701\u2013712. https:\/\/doi.org\/10.4093\/dmj.2022.0002","journal-title":"Diabetes Metab J"},{"issue":"24","key":"5290_CR4","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/ajhp\/zxad177","volume":"80","author":"SR Bermudez","year":"2023","unstructured":"Bermudez SR, Anderson JR, Bos AJ, Ray GM (2023) Utilization rates and predictors of sodium glucose cotransporter 2 inhibitor use in patients with heart failure with or without type 2 diabetes. Am J Health-Syst Pharm 80(24):1787\u20131795. https:\/\/doi.org\/10.1093\/ajhp\/zxad177","journal-title":"Am J Health-Syst Pharm"},{"issue":"10","key":"5290_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102779","volume":"49","author":"LM Burgos","year":"2024","unstructured":"Burgos LM, Ballari FN, Spaccavento A et al (2024) In-hospital initiation of sodium-glucose cotransporter-2 inhibitors in patients with heart failure and reduced ejection fraction: 90-day prescription patterns and clinical implications. Curr Probl Cardiol 49(10):102779. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102779","journal-title":"Curr Probl Cardiol"},{"issue":"3","key":"5290_CR6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/ejhf.3444","volume":"27","author":"R Christodorescu","year":"2025","unstructured":"Christodorescu R, Geavlete O, Ferrini M et al (2025) Translating the 2021 ESC heart failure guideline recommendations in daily practice: Results from a heart failure survey. A scientific statement of the ESC Council for Cardiology Practice and the Heart Failure Association of the ESC. Eur J Heart Fail 27(3):412\u2013420. https:\/\/doi.org\/10.1002\/ejhf.3444","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"5290_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s40256-024-00697-7","volume":"25","author":"BB Das","year":"2025","unstructured":"Das BB, Niu J (2025) A systematic review and meta-analysis of the safety and efficacy of SGLT2 inhibitors in chronic heart failure in ACHD patients. Am J Cardiovasc Drugs 25(2):231\u2013240. https:\/\/doi.org\/10.1007\/s40256-024-00697-7","journal-title":"Am J Cardiovasc Drugs"},{"issue":"5","key":"5290_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cells14050324","volume":"14","author":"O Fonseka","year":"2025","unstructured":"Fonseka O, Gare SR, Chen X et al (2025) Molecular mechanisms underlying heart failure and their therapeutic potential. Cells 324. https:\/\/doi.org\/10.3390\/cells14050324","journal-title":"Cells"},{"issue":"1","key":"5290_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-024-03961-5","volume":"24","author":"J Gonzalez","year":"2024","unstructured":"Gonzalez J, Dave CV (2024) Prescribing trends of SGLT2 inhibitors among HFrEF and HFpEF patients with and without T2DM, 2013\u20132021. BMC Cardiovasc Disord 24(1):285. https:\/\/doi.org\/10.1186\/s12872-024-03961-5","journal-title":"BMC Cardiovasc Disord"},{"issue":"11","key":"5290_CR10","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1089\/jwh.2023.0059","volume":"32","author":"A Hammer","year":"2023","unstructured":"Hammer A, Hofer F, Kazem N et al (2023) Sex-Related Disparities in Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Type 2 Diabetes and Heart Failure. J Womens Health 32(11):1219\u20131228. https:\/\/doi.org\/10.1089\/jwh.2023.0059","journal-title":"J Womens Health"},{"issue":"18","key":"5290_CR11","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the american college of Cardiology\/American heart association joint committee on clinical practice guidelines. Circulation 145(18):e895\u2013e1032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"issue":"3","key":"5290_CR12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10557-021-07234-7","volume":"36","author":"F Hofer","year":"2022","unstructured":"Hofer F, Kazem N, Richter B et al (2022) Prescription patterns of Sodium-Glucose cotransporter 2 inhibitors and cardiovascular outcomes in patients with diabetes mellitus and heart failure. Cardiovasc Drugs Ther 36(3):497\u2013504. https:\/\/doi.org\/10.1007\/s10557-021-07234-7","journal-title":"Cardiovasc Drugs Ther"},{"issue":"8","key":"5290_CR13","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1002\/ejhf.3260","volume":"26","author":"RM Inciardi","year":"2024","unstructured":"Inciardi RM, Vaduganathan M, Lombardi CM et al (2024) OPTImal PHARMacological therapy for patients with heart failure: Rationale and design of the OPTIPHARM-HF registry. Eur J Heart Fail 26(8):1707\u20131714. https:\/\/doi.org\/10.1002\/ejhf.3260","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"5290_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2025.102990","volume":"50","author":"JM Jim\u00e9nez","year":"2025","unstructured":"Jim\u00e9nez JM, Restrepo LJ, Villa M et al (2025) Guideline-directed medical therapy for heart failure: Real-world evidence in one Latin-American center. Curr Probl Cardiol 50(3):102990. https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.102990","journal-title":"Curr Probl Cardiol"},{"issue":"3","key":"5290_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.tcm.2024.10.002","volume":"35","author":"MM Kittleson","year":"2025","unstructured":"Kittleson MM (2025) Guidelines for treating heart failure. Trends Cardiovasc Med 35(3):141\u2013150. https:\/\/doi.org\/10.1016\/j.tcm.2024.10.002","journal-title":"Trends Cardiovasc Med"},{"issue":"1","key":"5290_CR16","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/ehf2.15049","volume":"12","author":"U Kocabas","year":"2025","unstructured":"Kocabas U, Ergin I, Yavuz V et al (2025) Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED-HEART study. ESC Heart Fail 12(1):434\u2013446. https:\/\/doi.org\/10.1002\/ehf2.15049","journal-title":"ESC Heart Fail"},{"key":"5290_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaf025","author":"C Lanier","year":"2025","unstructured":"Lanier C, Brumit JC, Tharp J et al (2025) Incidence and potential predictors of SGLT2 inhibitor initiation in acutely hospitalized patients with heart failure. Am J Health-Syst Pharm. https:\/\/doi.org\/10.1093\/ajhp\/zxaf025","journal-title":"Am J Health-Syst Pharm"},{"issue":"7","key":"5290_CR18","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/ejhf.3267","volume":"26","author":"J Malgie","year":"2024","unstructured":"Malgie J, Wilde MI, Clephas PRD et al (2024) Contemporary guideline-directed medical therapy in de novo, chronic, and worsening heart failure patients: first data from the TITRATE-HF study. Eur J Heart Fail 26(7):1549\u20131560. https:\/\/doi.org\/10.1002\/ejhf.3267","journal-title":"Eur J Heart Fail"},{"issue":"36","key":"5290_CR19","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"issue":"1","key":"5290_CR20","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/ehf2.14597","volume":"11","author":"S Mizobuchi","year":"2024","unstructured":"Mizobuchi S, Saito Y, Kitano D et al (2024) Sodium\u2010glucose co\u2010transporter 2 inhibitors in acute heart failure: real\u2010world prescription trends and outcomes analysis. ESC Heart Fail 11(1):410\u2013421. https:\/\/doi.org\/10.1002\/ehf2.14597","journal-title":"ESC Heart Fail"},{"issue":"8","key":"5290_CR21","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41581-024-00836-y","volume":"20","author":"DV O Hara","year":"2024","unstructured":"O Hara DV, Lam CSP, McMurray JJV et al (2024) Applications of SGLT2 inhibitors beyond glycaemic control. Nat Rev Nephrol 20(8):513\u2013529. https:\/\/doi.org\/10.1038\/s41581-024-00836-y","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"5290_CR22","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1002\/ehf2.15018","volume":"11","author":"Y Ono","year":"2024","unstructured":"Ono Y, Yoneda K, Okuyama N, Nagai T (2024) Characteristics and outcomes of heart failure in Japan: a hospital-based administrative database analysis. ESC Heart Fail 11(6):4360\u20134370. https:\/\/doi.org\/10.1002\/ehf2.15018","journal-title":"ESC Heart Fail"},{"issue":"15","key":"5290_CR23","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"issue":"3","key":"5290_CR24","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1002\/ehf2.15172","volume":"12","author":"S Paolillo","year":"2025","unstructured":"Paolillo S, Basile C, Marzano F et al (2025) Implementation of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction (OpTIMa-HF registry). ESC Heart Fail 12(3):1786\u20131795. https:\/\/doi.org\/10.1002\/ehf2.15172","journal-title":"ESC Heart Fail"},{"issue":"12","key":"5290_CR25","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387(12):1089\u20131098. https:\/\/doi.org\/10.1056\/NEJMoa2206286","journal-title":"N Engl J Med"},{"key":"5290_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S et al (2022) IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183. https:\/\/doi.org\/10.1016\/j.diabres.2021.109119","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"5290_CR27","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ejhf.3081","volume":"26","author":"D Tomasoni","year":"2024","unstructured":"Tomasoni D, Pagnesi M, Colombo G et al (2024) Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: an analysis from the HELP-HF registry. Eur J Heart Fail 26(2):327\u2013337. https:\/\/doi.org\/10.1002\/ejhf.3081","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"5290_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jchf.2024.08.004","volume":"13","author":"J Zheng","year":"2025","unstructured":"Zheng J, Sandhu AT, Bhatt AS et al (2025) Inpatient use of Guideline-Directed medical therapy during heart failure hospitalizations among Community-Based health systems. JACC: Heart Failure 13(1):43\u201354. https:\/\/doi.org\/10.1016\/j.jchf.2024.08.004","journal-title":"JACC: Heart Failure"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05290-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05290-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05290-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:43:19Z","timestamp":1783906999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05290-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5290"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05290-0","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Clinical Research Ethics Committee of Beijing Friendship Hospital, which waived the requirement for informed consent due to the retrospective nature of the study and as all procedures were part of routine care. To ensure confidentiality, all patient identifiers were anonymized during analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}